Article
Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database.
Gut - 1 Sept 2017
Møller Pål, Seppälä Toni, Bernstein Inge, Holinski-Feder Elke, Sala Paola, Evans D Gareth, Lindblom Annika, Macrae Finlay, Blanco Ignacio, Sijmons Rolf, Jeffries Jacqueline, Vasen Hans, Burn John, Nakken Sigve, Hovig Eivind, Rødland Einar Andreas, Tharmaratnam Kukatharmini, de Vos Tot Nederveen Cappel Wouter H, Hill James, Wijnen Juul, Jenkins Mark, Green Kate, Lalloo Fiona, Sunde Lone, Mints Miriam, Bertario Lucio, Pineda Marta, Navarro Matilde, Morak Monika, Renkonen-Sinisalo Laura, Frayling Ian M, Plazzer John-Paul, Pylvanainen Kirsi, Genuardi Maurizio, Mecklin Jukka-Pekka, Möslein Gabriela, Sampson Julian R, Capella Gabriel
Abstract excerpt
OBJECTIVE: Today most patients with Lynch syndrome (LS) survive their first cancer. There is limited information on the incidences and outcome of subsequent cancers. The present study addresses three questions: (i) what is the cumulative incidence of a subsequent cancer; (ii) in which organs do subsequent cancers occur; and (iii) what is the survival following these cancers? DESIGN: Information was collated on...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.